
NRSN Stock Forecast & Price Target
NRSN Analyst Ratings
Bulls say
NeuroSense Therapeutics Ltd is positioned favorably due to its positive clinical trial results, with the Phase 2b PARADIGM study achieving a statistically significant 29.2% slowing in disease progression for patients treated with its product candidate, PrimeC. The therapy demonstrated not only effectiveness but also favorable safety and tolerability, alongside biomarker-driven evidence of target engagement, reinforcing its potential as a viable treatment option. Additionally, the convergence of regulatory and clinical milestones is anticipated to spur opportunities for strategic partnerships in North America and Europe, further enhancing the company's growth prospects.
Bears say
NeuroSense Therapeutics Ltd is facing a concerning financial situation as its cash reserves are diminishing, indicating a potential liquidity crisis. The expectation of an impending capital raise suggests that the company may struggle to fund ongoing operations and clinical trials without additional financial support. This situation raises flags regarding the company's ability to execute its development plans for its key product candidate, PrimeC, which could adversely affect investor confidence and stock performance.
This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.
NRSN Analyst Forecast & Price Prediction
Start investing in NRSN
Order type
Buy in
Order amount
Est. shares
0 shares